(GMAB) Genmab AS - Ratings and Ratios
Antibody, Cancer, Lymphoma, Myeloma, Solid Tumors
GMAB EPS (Earnings per Share)
GMAB Revenue
Description: GMAB Genmab AS
Genmab A/S (NASDAQ:GMAB) is a Denmark-based biotech firm that creates antibody-based therapeutics for oncology and a range of other diseases. Its commercial portfolio includes EPKINLY and TEPKINLY for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Tivdak for metastatic cervical cancer after chemotherapy failure. The pipeline spans multiple modalities-bispecific antibodies (e.g., epcoritamab), antibody-drug conjugates (e.g., tisotumab vedotin), and novel immune-modulating agents (e.g., Mim8 for hemophilia A)-targeting hematologic malignancies, solid tumors, and non-oncology indications such as multiple sclerosis and thyroid eye disease.
Key metrics (as of Q3 2024) show Genmab generating roughly $1.1 billion in total revenue, with ≈ $480 million coming from its partnership-driven products (e.g., DARZALEX with Janssen). R&D intensity remains high at ~ 23 % of sales, reflecting its expansive pipeline of > 30 candidates. The company’s cash runway extends through 2026, supported by long-term collaborations with AbbVie, Pfizer, Johnson & Johnson, Novartis, and others, which collectively contribute milestone payments and shared development risk.
Sector-level drivers that underpin Genmab’s outlook include the accelerating growth of the global antibody therapeutics market (CAGR ≈ 9 % through 2030) and increasing payer acceptance of bispecific and ADC platforms, which are expected to command higher pricing power relative to traditional monoclonal antibodies. Additionally, biotech financing conditions have tightened, making strategic alliances-like Genmab’s extensive partner network-a critical source of non-dilutive capital.
For a deeper, data-rich analysis of Genmab’s valuation assumptions and scenario modeling, you might find the research tools on ValueRay useful as a next step.
GMAB Stock Overview
| Market Cap in USD | 20,418m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2009-06-01 |
GMAB Stock Ratings
| Growth Rating | -5.30% |
| Fundamental | 85.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 13.6% |
| Analyst Rating | 4.0 of 5 |
GMAB Dividends
Currently no dividends paidGMAB Growth Ratios
| Growth Correlation 3m | 95.5% |
| Growth Correlation 12m | 44.1% |
| Growth Correlation 5y | -76% |
| CAGR 5y | -7.49% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.12 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.21 |
| Sharpe Ratio 12m | 1.88 |
| Alpha | 16.82 |
| Beta | 0.818 |
| Volatility | 62.67% |
| Current Volume | 3143.4k |
| Average Volume 20d | 2238.7k |
| Stop Loss | 28.9 (-4.1%) |
| Signal | -0.14 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (7.44b TTM) > 0 and > 6% of Revenue (6% = 1.37b TTM) |
| FCFTA 0.16 (>2.0%) and ΔFCFTA -0.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 91.29% (prev 92.65%; Δ -1.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 7.09b <= Net Income 7.44b (YES >=105%, WARN >=100%) |
| Net Debt (-7.27b) to EBITDA (7.66b) ratio: -0.95 <= 3.0 (WARN <= 3.5) |
| Current Ratio 6.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (619.9m) change vs 12m ago -4.46% (target <= -2.0% for YES) |
| Gross Margin 94.46% (prev 96.83%; Δ -2.37pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 57.24% (prev 49.11%; Δ 8.12pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 55.01 (EBITDA TTM 7.66b / Interest Expense TTM 134.0m) >= 6 (WARN >= 3) |
Altman Z'' 9.46
| (A) 0.51 = (Total Current Assets 24.78b - Total Current Liabilities 3.99b) / Total Assets 40.96b |
| (B) 0.56 = Retained Earnings (Balance) 22.80b / Total Assets 40.96b |
| (C) 0.19 = EBIT TTM 7.37b / Avg Total Assets 39.79b |
| (D) 2.92 = Book Value of Equity 21.53b / Total Liabilities 7.36b |
| Total Rating: 9.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 85.83
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 5.89% = 2.95 |
| 3. FCF Margin 29.32% = 7.33 |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda -0.95 = 2.50 |
| 6. ROIC - WACC (= 20.57)% = 12.50 |
| 7. RoE 21.90% = 1.82 |
| 8. Rev. Trend 63.59% = 4.77 |
| 9. EPS Trend 29.27% = 1.46 |
What is the price of GMAB shares?
Over the past week, the price has changed by -8.00%, over one month by +5.35%, over three months by +38.91% and over the past year by +32.27%.
Is Genmab AS a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GMAB is around 29.29 USD . This means that GMAB is currently overvalued and has a potential downside of -2.79%.
Is GMAB a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GMAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 37.5 | 24.6% |
| Analysts Target Price | 37.5 | 24.6% |
| ValueRay Target Price | 32.8 | 8.9% |
Last update: 2025-10-20 03:53
GMAB Fundamental Data Overview
P/E Trailing = 17.1865
P/E Forward = 14.556
P/S = 5.5987
P/B = 3.729
P/EG = 1.0776
Beta = 0.818
Revenue TTM = 22.78b DKK
EBIT TTM = 7.37b DKK
EBITDA TTM = 7.66b DKK
Long Term Debt = 148.0m DKK (from capitalLeaseObligations, last quarter)
Short Term Debt = 101.4m DKK (from shortTermDebt, last quarter)
Debt = 937.9m DKK (from shortLongTermDebtTotal, last quarter)
Net Debt = -7.27b DKK (from netDebt column, last quarter)
Enterprise Value = 113.33b DKK (130.76b + Debt 937.9m - CCE 18.37b)
Interest Coverage Ratio = 55.01 (Ebit TTM 7.37b / Interest Expense TTM 134.0m)
FCF Yield = 5.89% (FCF TTM 6.68b / Enterprise Value 113.33b)
FCF Margin = 29.32% (FCF TTM 6.68b / Revenue TTM 22.78b)
Net Margin = 32.65% (Net Income TTM 7.44b / Revenue TTM 22.78b)
Gross Margin = 94.46% ((Revenue TTM 22.78b - Cost of Revenue TTM 1.26b) / Revenue TTM)
Gross Margin QoQ = 93.84% (prev 94.13%)
Tobins Q-Ratio = 2.77 (Enterprise Value 113.33b / Total Assets 40.96b)
Interest Expense / Debt = 6.08% (Interest Expense 57.0m / Debt 937.9m)
Taxrate = 20.57% (551.3m / 2.68b)
NOPAT = 5.86b (EBIT 7.37b * (1 - 20.57%))
Current Ratio = 6.22 (Total Current Assets 24.78b / Total Current Liabilities 3.99b)
Debt / Equity = 0.03 (Debt 937.9m / totalStockholderEquity, last quarter 33.60b)
Debt / EBITDA = -0.95 (Net Debt -7.27b / EBITDA 7.66b)
Debt / FCF = -1.09 (Net Debt -7.27b / FCF TTM 6.68b)
Total Stockholder Equity = 33.95b (last 4 quarters mean from totalStockholderEquity)
RoA = 18.15% (Net Income 7.44b / Total Assets 40.96b)
RoE = 21.90% (Net Income TTM 7.44b / Total Stockholder Equity 33.95b)
RoCE = 21.62% (EBIT 7.37b / Capital Employed (Equity 33.95b + L.T.Debt 148.0m))
RoIC = 29.57% (NOPAT 5.86b / Invested Capital 19.80b)
WACC = 9.00% (E(130.76b)/V(131.70b) * Re(9.03%) + D(937.9m)/V(131.70b) * Rd(6.08%) * (1-Tc(0.21)))
Discount Rate = 9.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.93%
[DCF Debug] Terminal Value 78.30% ; FCFE base≈6.61b ; Y1≈8.16b ; Y5≈13.92b
Fair Price DCF = 320.2 (DCF Value 197.08b / Shares Outstanding 615.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 29.27 | EPS CAGR: -45.87% | SUE: -2.10 | # QB: 0
Revenue Correlation: 63.59 | Revenue CAGR: 14.01% | SUE: 0.02 | # QB: 0
Additional Sources for GMAB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle